A diversified Pipeline

We are dedicated to advancing our deep and diversified pipeline to create new standards of care for patients in need of better options. We leverage our scientific excellence to create differentiated ideas, identify unique targets, and select the optimal modality to develop transformative therapeutics across a wide variety of cancer and autoimmune indications.
Image of Circles

Programs Spanning a Range of Indications and Platforms

Taking a modality-agnostic approach offers incredible freedom to develop the most effective therapies. Our methodology has resulted in a pipeline of clinical-stage programs with diverse targets, mechanisms, and modalities.

Patients also need more tolerable treatments. We employ strategies to improve response, minimize toxicity, and allow more patient-friendly dosing.

Diverse Diseases Require a Diverse Approach to Research and Development

Programs Underway
Zipalertinib (CLN-081/TAS6417)
Early Programs
TCR-based Therapy Targeting a Peptide-MHC Complex
HPK1 Targeting: Potential first-in-class degrader of a protein that acts as a negative regulator of T cells and TCR signaling
All of Cullinan's molecules are investigational; safety and efficacy have not been established; they have not been approved by any health authority.
Descriptions of asset MOAs are based on pre-clinical data.

A Deep And Diversified Pipeline

Our clinical programs span a range of indications and modalities.

Harnessing Science for Patient Benefit

Our clinical trials are designed with clinically relevant endpoints and predefined benchmarks for success.